Charles W Meredith
Affiliation: University of Washington
- Implications of chronic methamphetamine use: a literature reviewCharles W Meredith
Department of Psychiatry and Behavioral Sciences, University of Washington, and VA Puget Sound Health Care System S 116 ATC, 1160 S Columbian Way, Seattle, WA 98108, USA
Harv Rev Psychiatry 13:141-54. 2005..Atypical antipsychotics may have some promise in this regard...
- Open trial of injectable risperidone for methamphetamine dependenceCharles W Meredith
From the Mental Health Service CWM, JPR, CAM, EVY, AK, LCF, Amt, and AJS, Center of Excellence in Substance Abuse Treatment and Education CAM, LCF, and AJS, VA Puget Sound Health Care System and Department of Psychiatry and Behavioral Sciences CWM, CJ, MC, LCF, Amt, and AJS, University of Washington, Seattle, WA
J Addict Med 3:55-65. 2009..However, these results are limited by the use of an open trial design with a high dropout rate. Risperidone deserves further study in controlled trials as a pharmacotherapy for MA dependence...
- An open-label pilot study of risperidone in the treatment of methamphetamine dependenceCharles W Meredith
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
J Psychoactive Drugs 39:167-72. 2007..0 (SD = 8.4) to 51.8 (SD = 8.3; t = 2.7, p <.05), and positive symptom distress declined from a mean of 52.8 (SD =8.0) to 41.7 (SD = 8.6; t= 3.0, p <.05). Risperidone was well tolerated and associated with decreased MA use...
- A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependenceTracy L Simpson
Center of Excellence in Substance Abuse Treatment and Education, University of Washington, Seattle, WA 98108, USA
Alcohol Clin Exp Res 33:255-63. 2009..Theory and preclinical evidence suggest that noradrenergic circuits may be involved in alcohol reinforcement and relapse. We therefore tested the alpha-1 adrenergic receptor antagonist, prazosin, as a pharmacotherapy for AD...